Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Mugen1996on Jan 03, 2011 1:37pm
357 Views
Post# 17918629

RE: Year End Results...

RE: Year End Results...As someone previously reported:
https://www.ibx.com/providers/communications/news/2010/self_injectable_drugs.html
Looks like someone is willing to pay....

Changes to Our Self-Injectable Drugs Policy

Effective January 1, 2011, the following two changes will be made to Medical Policy #08.00.78: Self-Injectable Drugs:

  • Intron A®, which includes Intron A Pen®, will be removed from the policy and will not be available under the pharmacy benefit. It will only be available under the medical benefit, and providers may begin billing for Intron A® under the medical benefit effective December 8, 2010.
  • Tesamorelin (Egrifta) will be added to the Self-Injectable Drugs policy in anticipation of approval from the U.S. Food and Drug Administration (FDA). Tesamorelin (Egrifta) will only be made available under the pharmacy benefit and is not eligible for coverage until the drug receives FDA approval.

Please read the full article in the December issue of Partners in Health UpdateSM for more information about these changes, including how your patients can have drugs shipped directly to their home or your office.

Bullboard Posts